An Orally Active Selective Androgen Receptor Modulator Is Efficacious on Bone, Muscle, and Sex Function with Reduced Impact on Prostate
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
A number of conditions, including osteoporosis, frailty, and sexual dysfunction in both men and women have been improved using androgens. However, androgens are not widely used for these indications because of the side effects associated with these drugs. We describe an androgen receptor (AR) ligand that maintains expected anabolic activities with substantially diminished activity in the prostate. LGD2226 is a nonsteroidal, nonaromatizable, highly selective ligand for the AR, exhibiting virtually no affinity for the other intracellular receptors. We determined that AR bound to LGD2226 exhibits a unique pattern of protein-protein interactions compared with testosterone, fluoxymesterone (an orally available steroidal androgen), and other steroids, suggesting that LGD2226 alters the conformation of the ligand-binding domain. We demonstrated that LGD2226 is fully active in cell-based models of bone and muscle. LGD2226 exhibited anabolic activity on muscle and bone with reduced impact on prostate growth in rodent models. Biomechanical testing of bones from animals treated with LGD2226 showed strong enhancement of bone strength above sham levels. LGD2226 was also efficacious in a sex-behavior model in male rats measuring mounts, intromissions, ejaculations, and copulation efficiency. These results with an orally available, nonaromatizable androgen demonstrate the important role of the AR and androgens in mediating a number of beneficial effects in bone, muscle, and sexual function independent from the conversion of androgens into estrogenic ligands. Taken together, these results suggest that orally active, nonsteroidal selective androgen receptor modulators may be useful therapeutics for enhancing muscle, bone, and sexual function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reversal of Bone Loss in Mice by Nongenotropic Signaling of Sex Steroids
Kousteni, S., Chen, J.-R., Bellido, T., Han, L., Ali, A. A., O'Brien, C. A., Plotkin, L., Fu, Q., Mancino, A. T., Wen, Y., et al. (2002) · Science · doi:10.1126/science.1074935 · Cited by 420
Aversa, A., Isidori, A. M., Spera, G., Lenzi, A., & Fabbri, A. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01764.x · Cited by 343
Brain masculinization requires androgen receptor function
Sato, T., Matsumoto, T., Kawano, H., Watanabe, T., Uematsu, Y., Sekine, K., Fukuda, T., Aihara, K.-I., Krust, A., Yamada, T., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0305303101 · Cited by 303
Turner, R. T., Wakley, G. K., & Hannon, K. S. (1990) · Journal of Orthopaedic Research · doi:10.1002/jor.1100080418 · Cited by 238
Self-citationSchaufele, F., Carbonell, X., Guerbadot, M., Borngraeber, S., Chapman, M. S., Ma, A. A. K., Miner, J. N., & Diamond, M. I. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408819102 · Cited by 208 · cited 1×
“The AR N terminus is bound to the C terminus in the presence of hormone in living cells (24).”
BackgroundSelf-citationMcNicholas, T. A., Dean, J. D., Mulder, H., Carnegie, C., & Jones, N. A. (2003) · BJU International · doi:10.1046/j.1464-410x.2003.04016.x · Cited by 178 · cited 1×
“Supplemental topical androgens have provided benefit in a number of clinical trials (52, 53), but their use is confounded by prostate-related side effects in men and androgenic side effects in women as well as skin irritation at the site of application in both sexes.”
BackgroundGrumbach, M. M. (2000) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2000-s619 · Cited by 173
Cited by
Advances in Male Contraception
Page, S. T., Amory, J. K., & Bremner, W. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0041 · Cited by 1,134
Estrogens and androgens in skeletal physiology and pathophysiology
Almeida, M., Laurent, M. R., Dubois, V., Claessens, F., O'Brien, C. A., Bouillon, R., Vanderschueren, D., & Manolagas, S. C. (2017) · Physiological Reviews · doi:10.1152/physrev.00033.2015 · Cited by 860
Pope, H. G., Wood, R. I., Rogol, A., Nyberg, F., Bowers, L., & Bhasin, S. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1058 · Cited by 658
Sex Steroid Actions in Male Bone
Vanderschueren, D., Laurent, M. R., Claessens, F., Gielen, E., Lagerquist, M. K., Vandenput, L., Börjesson, A. E., & Ohlsson, C. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1024 · Cited by 327
Nuclear Receptors and Their Selective Pharmacologic Modulators
Burris, T. P., Solt, L. A., Wang, Y., Crumbley, C., Banerjee, S., Griffett, K., Lundasen, T., Hughes, T., & Kojetin, D. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006833 · Cited by 283
Development of selective androgen receptor modulators (SARMs)
Narayanan, R., Coss, C. C., & Dalton, J. T. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.06.013 · Cited by 251
Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications
Solomon, Z. J., Mirabal, J. R., Mazur, D. J., Kohn, T. P., Lipshultz, L. I., & Pastuszak, A. W. (2019) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2018.09.006 · Cited by 174
“[33] Similar to the preclinical data discussed above in regards to SARMs and female sexual function, treatment of male rats with SARMs led to increased sexual behavior.[34] Male rats treated with LGD226, a synthetic SARM, displayed an increased number of mounts, intromissions, and ejaculations compared with a control…”
ResultTreatment of hypogonadism: Current and future therapies
Thirumalai, A., Berkseth, K. E., & Amory, J. K. (2017) · F1000Research · doi:10.12688/f1000research.10102.1 · Cited by 36
Bhattacharya, I., Tarabar, S., Liang, Y., Pradhan, V., Owens, J., & Oemar, B. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.03.025 · Cited by 30
“Fatigue 0 1 (1) 0 0 0 0 0 0 0 0 0 1 (1) 0 0 0 1 (1) Investigations 0 0 0 0 0 0 0 1 (1) 0 1 (0) 0 0 0 5 (5) 1 (1) 3 (3) Alanine aminotransferase increased 0 0 0 0 0 0 0 1 (1) 0 1 (0) 0 0 0 5 (5) 1 (1) 3 (3)”
Is There Room for SERMs or SARMs as Alternative Therapies for Adult Male Hypogonadism?
Giagulli, V. A., Silvestrini, A., Bruno, C., Triggiani, V., Mordente, A., & Mancini, A. (2020) · International Journal of Endocrinology · doi:10.1155/2020/9649838 · Cited by 14
Testosterone Therapy for Osteoporosis in Men
Lakshman, K. M., Bhasin, S., & Araujo, A. B. (2010) · Osteoporosis in Men · doi:10.1016/b978-0-12-374602-3.00056-0 · Cited by 1
Metadata
- Authors
- Miner, J. N., Chang, W., Chapman, M. S., Finn, P. D., Hong, M. H., López, F. J., Marschke, K. B., Rosen, J., Schrader, W., Turner, R., van Oeveren, A., Viveros, H., Zhi, L., & Negro-Vilar, A.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2007-01
- Volume
- 148
- Issue
- 1
- Pages
- 363-373
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2015620666
- Cited by
- 136
- References
- 7
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.